ArticleClinical pharmacology : advances and applications2021
Efficacy of Generic Atorvastatin in a Real-World Setting.
Article in Clinical pharmacology : advances and applications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Can Generic Medications Be a Safe and Effective Alternative to Brand-Name Drugs for Cardiovascular Disease Treatment? A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2025Pooled it
- Cardiac function and mortality of stem cell therapy in patients with coronary artery disease who underwent coronary artery bypass graft without heart failure: A meta-analysis.Biomedical reports · 2025Article
- Switching Therapy to the Second Brand of Generic Atorvastatin: A 6-Month Retrospective Cohort, Real-World Study.Drugs - real world outcomes · 2025Article
- An association between heart rate variability and pediatric obstructive sleep apnea.Italian journal of pediatrics · 2024Article
- Clinical predictive factors of coronary stenosis in patients with high‑risk valvular heart disease who received diagnostic coronary angiography prior to cardiac valve surgery.Biomedical reports · 2024Article
- Marketing factors associated with a continuous positive airway pressure machine purchasing in patients with obstructive sleep apnea.Future science OA · 2023Article
- Leukoaraiosis and stroke severity scores in post-rtPA intracerebral haemorrhage.BMJ neurology open · 2023Article
- Risk factors of left ventricular hypertrophy in obstructive sleep apnea.Biomedical reports · 2023Article
- Adherence to Continuous Positive Airway Pressure Therapy in Pediatric Patients with Obstructive Sleep Apnea: A Meta-Analysis.Therapeutics and clinical risk management · 2023Review
- Impact of COVID-19 outbreak on stroke admission in Thailand: a quasi-experimental, ecological study on national database.Infection ecology & epidemiology · 2023Article
- Factors associated with favorable outcomes in acute severe stroke patients: A real-world, national database study.Biomedical reports · 2022Article
- A meta-analysis to identify factors associated with CPAP machine purchasing in patients with obstructive sleep apnea.Biomedical reports · 2022Article
- A surveillance for hepatitis C virus infection in northeastern, Thailand: a 10-year cohort.Journal of preventive medicine and hygiene · 2022Article
- Editorial: Clinical aspects of obstructive sleep apnea and cardiovascular consequences.Frontiers in neurology · 2022Article
- Clinical Characteristics and Outcomes of Patients with Intracerebral Hemorrhage: Nonsurgical Versus Surgical Treatment.Journal of emergencies, trauma, and shockArticle
- Are calcium channel blockers related to lung cancer?Drug target insightsArticle
- PIVKA-II or AFP has better diagnostic properties for hepatocellular carcinoma diagnosis in high-risk patients.Journal of circulating biomarkersArticle
- Prevalence and risk factors for persistent atrial fibrillation in obstructive sleep apnea.Sleep science (Sao Paulo, Brazil)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe ability of statins to reduce LDL-c plays an important role in both primary and secondary prevention of atherosclerotic cardiovascular diseases. Such treatment can often be costly, but using generic atorvastatin may reduce cost by up to US$2635. In addition, a previous 8-week study found that it exhibited comparable efficacy to the brand-name medication. This study aimed to evaluate the efficacy of generic atorvastatin over a longer period of six months in a real-world setting.
methodsThis was a retrospective cohort study in adult patients who had received brand-name atorvastatin for at least three months and then had switched to generic atorvastatin for at least six months. Lipid and safety profiles were evaluated at six months after switching. Adjusted analyses for age, sex, co-morbid disease, dosage, and indications for statin therapy were also performed.
resultsDuring the study period, there were 488 patients who met the study criteria. The mean (SD) age of the patients was 60.97 (12.26) years, and 48.36% were male (236 patients). At six months, average total cholesterol, HDL-c, and LDL-c were all lower, from 174.43 to 166.15 mg/dL, from 51.64 to 49.51 mg/dL, and from 110.08 to 100.78 mg/dL (p < 0.001), respectively. There were no significant differences in terms of any other laboratory test results. LDL-c exhibited the highest significant reduction at 9.30 mg/dL. Stratified analyses by age, sex, co-morbid disease, dose, and indications for statin therapy revealed similar decreases in HDL-c and LDL-c as in the study population as a whole.
conclusionGeneric atorvastatin resulted in significantly lower LDL-c than name-brand atorvastatin but less of an increase in HDL-c.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.